Cargando…
Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective
Advanced Therapy Medicinal Products (ATMPs) comprising cell, gene, and tissue-engineered therapies have demonstrated enormous therapeutic benefits. However, their development is complex to be managed efficiently within currently existing regulatory frameworks. Legislation and regulation requirements...
Autores principales: | Pizevska, Maja, Kaeda, Jaspal, Fritsche, Enrico, Elazaly, Hisham, Reinke, Petra, Amini, Leila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851388/ https://www.ncbi.nlm.nih.gov/pubmed/35186986 http://dx.doi.org/10.3389/fmed.2022.757647 |
Ejemplares similares
-
Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective
por: Amini, Leila, et al.
Publicado: (2023) -
Education for the translation of Advanced Therapy Medicinal Products
por: Adamo, Davide, et al.
Publicado: (2023) -
Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe
por: Farkas, Andreas M., et al.
Publicado: (2017) -
RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe—Why the European Union Should Invest More!
por: Goldsobel, Gady, et al.
Publicado: (2021) -
Imprecise Data and Their Impact on Translational Research in Medicine
por: Capobianco, Enrico
Publicado: (2020)